Lenalidomide in MDS: 4th time's a charm

Blood

Volumn 118, Issue 14, 2011, Pages 3757-3758

  Sekeres, Mikkael A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; LENALIDOMIDE; PLACEBO;

5Q- SYNDROME; CANCER GROWTH; CROSSOVER PROCEDURE; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HUMAN; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; SURVIVAL; TREATMENT RESPONSE;

EID: 80053649384     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-369009     Document Type: Note

References (8)

1. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate- 1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-3776.
2. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5qMDS by lenalidomide. Proc Natl Acad Sci U S A. 2009;106(31):12974-12979.
3. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-339.
4. List A, Kurtin S, Roe D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. NEngl J Med. 2005;352(6):549-557. (Pubitemid 40204668)
5. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. NEngl J Med. 2006;355(14):1456-1465. (Pubitemid 44511560)
6. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate- 1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86-93.
7. Germing U, Lauseker M, Hildebrandt B, et al. Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDSand Del(5q) [abstract]. ASH Annual Meeting Abstracts. 2009;114:945.
8. Cheson BD, Bennett JM, Kantarjian H, et al. Myelodysplastic syndromes standardized response criteria: further definition. Blood. 2001;98(6):1985.